BSX250117P70000
- 0.18
- 0.000.00%
Boston Scientific Newsroom
Baird Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $112
Barclays Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $111
Goldman Sachs Adjusts Price Target on Boston Scientific to $113 From $103
Barclays Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $111
Barclays Raises Boston Scientific Price Target to $111 From $86, Maintains Overweight Rating
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $110
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $100 to $110
Boston Scientific (BSX) Gets a Buy From TD Cowen
RBC Capital Reaffirms Their Buy Rating on Boston Scientific (BSX)
Boston Scientific's Promising Trial Outcomes and Market Expansion Drive Buy Rating
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $107
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $107
Baird Adjusts Price Target on Boston Scientific $104 From $102, Keeps Outperform Rating
Buy Rating for Boston Scientific Driven by Strong PFA Technology Adoption and Market Dynamics
Deutsche Bank Upgrades Boston Scientific(BSX.US) to Buy Rating, Raises Target Price to $108
Truist Financial Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $110
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $95 to $110
Bernstein Adjusts Price Target on Boston Scientific to $110 From $100, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)
Bernstein Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $100